Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer
- PMID: 24812058
- DOI: 10.1530/ERC-13-0514
Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer
Abstract
Zinc finger E-box-binding protein 2 (ZEB2) is known to help mediate the epithelial-to-mesenchymal transition, and thereby it facilitates cancer metastasis. This study was initiated to explore whether ZEB2 expression differs in prostate cancer (PCa, n=7) and benign prostatic hyperplasia (BPH, n=7) tissues. In PCa tissues, the levels of both immunoreactive ZEB2 and androgen receptor (AR) were found to be significantly higher (P<0.05) when compared with BPH tissues. Co-regulation of AR and ZEB2 prompted us to investigate the role of androgenic stimuli in ZEB2 expression. ZEB2 expression was found to be significantly (P<0.05) upregulated after androgen stimulation and downregulated following AR silencing in LNCaP cells, an androgen-dependent PCa cell line. This finding suggested AR as a positive regulator of ZEB2 expression in androgen-dependent cells. Paradoxically, androgen-independent (AI) cell lines PC3 and DU145, known to possess low AR levels, showed significantly (P<0.05) higher expression of ZEB2 compared with LNCaP cells. Furthermore, forced expression of AR in PC3 (PC3-AR) and DU145 (DU-AR) cells led to reductions in ZEB2 expression, invasiveness, and migration. These cells also exhibited an increase in the levels of E-cadherin (a transcriptional target of ZEB2). Co-transfection of AR and ZEB2 cDNA constructs prevented the decline in invasiveness and migration to a significant extent. Additionally, ZEB2 downregulation was associated with an increase in miR200a/miR200b levels in PC3-AR cells and with a decrease in miR200a/miR200b levels in AR-silenced LNCaP cells. Thus, AR acts as a positive regulator of ZEB2 expression in androgen-dependent cells and as a negative regulator in AI PCa cells.
Keywords: EMT; ZEB2; androgen receptor; prostate cancer.
Similar articles
-
Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer.Am J Pathol. 2015 Feb;185(2):293-301. doi: 10.1016/j.ajpath.2014.10.012. Epub 2014 Nov 26. Am J Pathol. 2015. PMID: 25432062 Free PMC article. Review.
-
Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.J Steroid Biochem Mol Biol. 2014 Sep;143:29-39. doi: 10.1016/j.jsbmb.2014.02.005. Epub 2014 Feb 22. J Steroid Biochem Mol Biol. 2014. PMID: 24565564
-
The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor.Urol Oncol. 2013 Oct;31(7):1117-23. doi: 10.1016/j.urolonc.2011.11.030. Epub 2012 Jan 20. Urol Oncol. 2013. PMID: 22264502
-
Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.Cancer Res. 2009 Oct 15;69(20):8141-9. doi: 10.1158/0008-5472.CAN-09-0919. Epub 2009 Oct 6. Cancer Res. 2009. PMID: 19808968
-
The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer.Mol Cell Biochem. 2003 Nov;253(1-2):89-101. doi: 10.1023/a:1026057402945. Mol Cell Biochem. 2003. PMID: 14619959 Review.
Cited by
-
MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4/STAT3 axis.Exp Mol Med. 2022 Aug;54(8):1290-1305. doi: 10.1038/s12276-022-00837-6. Epub 2022 Aug 30. Exp Mol Med. 2022. PMID: 36042375 Free PMC article.
-
The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer.Int J Biol Sci. 2021 Jul 25;17(13):3288-3304. doi: 10.7150/ijbs.63300. eCollection 2021. Int J Biol Sci. 2021. PMID: 34512147 Free PMC article.
-
Role of microRNA-129 in cancer and non-cancerous diseases (Review).Exp Ther Med. 2021 Sep;22(3):918. doi: 10.3892/etm.2021.10350. Epub 2021 Jun 30. Exp Ther Med. 2021. PMID: 34335879 Free PMC article. Review.
-
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair.Nat Commun. 2021 Jan 15;12(1):401. doi: 10.1038/s41467-020-20513-5. Nat Commun. 2021. PMID: 33452241 Free PMC article.
-
Dynamics of Cellular Plasticity in Prostate Cancer Progression.Front Mol Biosci. 2020 Jul 10;7:130. doi: 10.3389/fmolb.2020.00130. eCollection 2020. Front Mol Biosci. 2020. PMID: 32754615 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials